These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 33566985)

  • 1. OCCURRENCE OF UNUSUAL HAEMOGLOBINOPATHIES IN BALOCHISTAN: HB SD AND HB SE - PRESENTATION WITH OSTEOMYELITIS.
    Tauseef U; Anjum M; Ibrahim M; Baqai HS; Tauseef A; Tauseef M; Asghar MS; Zafar M; Rasheed U; Shaikh N
    Rev Paul Pediatr; 2021; 39():e2019365. PubMed ID: 33566985
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Haemoglobin sickle D disease: A presentation with ischaemic stroke.
    Afzal H; Umair SF
    J Pak Med Assoc; 2016 Mar; 66(3):348-50. PubMed ID: 26968293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and molecular characterization of Hb Hofu in eastern India.
    Purohit P; Mashon RS; Patel S; Dehury S; Pattanayak C; Das K; Nair S; Italia K; Bag S; Colah R; Patel DK
    Int J Lab Hematol; 2014 Feb; 36(1):71-6. PubMed ID: 23889802
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chromatographic analysis of Hb S for the diagnosis of various sickle cell disorders in Pakistan.
    Hashmi NK; Moiz B; Nusrat M; Hashmi MR
    Ann Hematol; 2008 Aug; 87(8):639-45. PubMed ID: 18465131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Using DNA testing for the precise, definite, and low-cost diagnosis of sickle cell disease and other Haemoglobinopathies: findings from Tanzania.
    Christopher H; Burns A; Josephat E; Makani J; Schuh A; Nkya S
    BMC Genomics; 2021 Dec; 22(1):902. PubMed ID: 34915846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Newborn screening for haemoglobinopathies: the Brussels experience.
    Gulbis B; Tshilolo L; Cotton F; Lin C; Vertongen F
    J Med Screen; 1999; 6(1):11-5. PubMed ID: 10321364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neonatal screening for sickle haemoglobinopathies in Birmingham.
    Griffiths KD; Raine DN; Mann JR
    Br Med J (Clin Res Ed); 1982 Mar; 284(6320):933-5. PubMed ID: 6802355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of high performance liquid chromatography (HPLC) pattern and prevalence of beta-thalassaemia trait among sickle cell disease patients in Lagos, Nigeria.
    Adeyemo T; Ojewunmi O; Oyetunji A
    Pan Afr Med J; 2014; 18():71. PubMed ID: 25400838
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neonatal screening for sickle cell disease and other hemoglobinopathies in "the changing Europe".
    Rolla R; Castagno M; Zaffaroni M; Grigollo B; Colombo S; Piccotti S; Dellora C; Bona G; Bellomo G
    Clin Lab; 2014; 60(12):2089-93. PubMed ID: 25651745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Haemoglobin SD disease--rare case of jaundice.
    Ghosh UC; Sen K; Narayan A; Banik KK; Saha PK
    J Indian Med Assoc; 2012 Jul; 110(7):501-2. PubMed ID: 23520682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of eight and a half years of neonatal screening for haemoglobinopathies in Birmingham.
    Griffiths PD; Mann JR; Darbyshire PJ; Green A
    Br Med J (Clin Res Ed); 1988 Jun; 296(6636):1583-5. PubMed ID: 3135019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Three sickle cell anemia patients each with a different alpha chain variant. Diagnostic complications.
    Gu LH; Wilson JB; Molchanova TP; McKie KM; McKie VC; Huisman TH
    Hemoglobin; 1993 Aug; 17(4):295-301. PubMed ID: 8226092
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-life experience with hydroxyurea in sickle cell disease: A multicenter study in a cohort of patients with heterogeneous descent.
    Rigano P; De Franceschi L; Sainati L; Piga A; Piel FB; Cappellini MD; Fidone C; Masera N; Palazzi G; Gianesin B; Forni GL;
    Blood Cells Mol Dis; 2018 Mar; 69():82-89. PubMed ID: 29107441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Utilization of monoclonal-antibody-based assay (HemoCard in screening for and differentiating between genotypes of sickle cell disease and other hemoglobinopathies.
    Schultz JC
    J Clin Lab Anal; 1995; 9(6):366-74. PubMed ID: 8587004
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hydroxyurea in the treatment of sickle-cell anemia.
    Howard LW; Kennedy LD
    Ann Pharmacother; 1997 Nov; 31(11):1393-6. PubMed ID: 9391697
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimising the screening for haemoglobinopathies in pregnancy planning.
    Nickel RS; Darbari DS; Martin B; Thaniel L; Stern H; Jacquot C
    Hum Fertil (Camb); 2023 Dec; 26(5):1334-1339. PubMed ID: 36942480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Barriers to the use of hydroxyurea in the management of sickle cell disease in Nigeria.
    Adeyemo TA; Diaku-Akinwunmi IN; Ojewunmi OO; Bolarinwa AB; Adekile AD
    Hemoglobin; 2019 May; 43(3):188-192. PubMed ID: 31462098
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expanding the role of hydroxyurea in children with sickle cell disease.
    Rogers ZR; Buchanan GR
    J Pediatr; 2004 Sep; 145(3):287-8. PubMed ID: 15343174
    [No Abstract]   [Full Text] [Related]  

  • 19. Sickle cell disease--pathophysiology and treatment.
    Redding-Lallinger R; Knoll C
    Curr Probl Pediatr Adolesc Health Care; 2006; 36(10):346-76. PubMed ID: 17055417
    [No Abstract]   [Full Text] [Related]  

  • 20. Sickle cell disease.
    Fixler J; Styles L
    Pediatr Clin North Am; 2002 Dec; 49(6):1193-210, vi. PubMed ID: 12580362
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.